Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose (Aphaia Technology, AT) in Obese Subjects

NCT05385978 is registered in ClinicalTrials.gov with Aphaia Pharma US LLC as lead sponsor.

NCT NCT05385978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05385978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose (Aphaia Technology, AT) in Obese Subjects
Lead sponsor
Aphaia Pharma US LLC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 1, 2022
Completion date
November 11, 2024
Enrollment
150 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

obese